SUPPLEMENTARY METHODS 25 26
Data source description 27 28 BIFAP (Base de Datos para la Investigación Farmacoepidemiológica en Atención 29 Primaria) is a database managed and fully funded by the Spanish Agency for Medicines 30 and Medical Devices (the Spanish Drug Regulatory Body) (www.bifap.org). 31
Autonomous Regions take part in BIFAP on a voluntary basis. 32
33
In 2015, BIFAP included prospectively recorded data from 5871 primary care physicians 34 (PCPs) (4910 general practitioners and 842 pediatricians) over the period 2002-2015. 35 BIFAP is updated yearly, being the total number of patients available of 7.9 million (49.7 36 million person-years). BIFAP does not include personal identifiers and its age and sex 37 distribution is comparable to the Spanish population, covering 17.0% of the total Spanish 38 population. This percentage increases to 55.5% if only the nine Autonomous Regions 39 collaborating in BIFAP are considered. Information available in BIFAP is that recorded 40 by the PCPs in their daily routine activities and includes demographics, drug 41 prescriptions, diagnoses, specialist referrals, clinical notes as free-text and other 42 additional health data (i.e. tests results, interventions, lifestyle information, etc). 43 44 Currently, two coding systems, with different levels of granularity, coexist in BIFAP: the 45 International Classification of Primary Care (ICPC) and the International Classification 46 of Diseases, version 9 (ICD-9). The ICPC is the coding system for eight out of nine 47 participant Autonomous Regions and its granularity is limited as compared to ICD-9 (686 48 vs 23222 codes respectively). 49
50
To identify the episode of interest by the PCP, the Electronic Health Care records (EHR) 51 software contains an internal thesaurus where a list of descriptors of diseases, signs or 52 symptoms is linked to the different dictionary codes. Often these descriptors provide more 53 detailed information than that in the corresponding code. Also, only for ICPC-based EHR 54 software, new descriptors can be included at local level and the PCPs can also modify or add information to the selected episode descriptor. This EHR software flexibility results 56 in a huge number of different diagnosis descriptors in BIFAP database (3.4 million). 57
58
To standardize this, BIFAP has developed its own research dictionary (ICPC-BIFAP) by 59 adding, to the most frequently used descriptors, a fourth digit to the original three-digit 60 ICPC code, increasing its granularity. In 2014, the ICPC-BIFAP dictionary included 5799 61 indexed terms. ICPC-BIFAP and ICD-9 codes covers about 93.2% of all diagnoses 62 recorded in BIFAP (116.7 million). 63
64
Pre-defined case-finding algorithms are available for a great number of diseases including 65 those most commonly used in pharmacoepidemiological research. Case-finding 66 algorithms are based on proper code selection within ICPC-BIFAP or ICD-9. To increase 67 its sensitivity, case-finding algorithms also include text mining strategies that identify the 68 disease of interest recorded as diagnosis by the PCP but not indexed with code in the 69 ICPC-BIFAP dictionary. 70 71
Case finding and selection 72 73
A predefined case-finding algorithm for acute myocardial infarction (AMI) is available 74 in BIFAP that includes ICPC -BIFAP codes K75 (acute myocardial infarction), ICD-9 75 code 410.9 (myocardial infarction) and free text search strategies of semantic related-76 terms. The case-finding algorithm identified 24231 cases. A random sample of 600 cases 77 were extracted for validation purposes. Two project investigators (SRM, DGB) 78 performed the validation blinded to any drug exposure after a run-in period aimed to reach 79 full concordance (defined as a kappa coefficient ≥ 0.9). Potential cases were considered 80 valid if they have either a diagnosis compatible with AMI (by code or free-text) plus 81 additional information confirming the diagnosis of AMI (e.g. confirmation by specialist, 82 hospitalization, positive enzymes, Q wave, revascularization procedures, compatible 83 antiplatelet treatment). The index date was considered the date of the first record, unless 84 the reviewers had evidence to support an earlier date. The overall positive predictive value 85 was 87.2% (95%CI 84.1%-89.8%). Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders 4-6. Table 1 (b) Indicate number of participants with missing data for each variable of interest Table 1 Outcome data 15* Report numbers in each exposure category, or summary measures of exposure Tables 2 and 3 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 
